MDC Partners Inc. (NASDAQ:MDCA) represented a move of 7.56 percent or $-0.75 per share and closed its previous day trading session at $9.6. 517428 Shares were traded in the last trading session with an Average Volume of 313.66 Million Shares. The stock currently has a Market Capitalization of 552.64 Million.
MDC Partners Inc. is a marketing communications firm providing marketing communication and consulting services throughout the United States, Canada, and the United Kingdom. Its services includes advertising and media, interactive marketing, direct marketing, public relations, corporate communications, market research, corporate identity and branding, and sales promotion. The Company also provides mobile marketing, and database and customer relationship management services. MDC Corporation Inc. is headquartered in Toronto, Canada.
The stock traded between $ 6.80 and $12.26 over 1-Year time period showing its price to sales ratio of 0.37. MDC Partners Inc. (NASDAQ:MDCA) is currently showing an INCREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-2.1 and 200-Day Simple Moving Average of $-3. Its Price to Free Cash Flow is 18.24 and Price to Book of 0.
Analyst’s recommended the stock as 2.2 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, MDC Partners Inc. (NASDAQ:MDCA) reported its Actual EPS of $0.24/share. The analysts offering Earnings Estimates for the company were believing that MDC Partners Inc. could bring EPS of $0.12/share. The difference between Actual EPS and Estimated EPS was 0.12 Percent. Thus showing an Earnings Surprise of 100 Percent.
GenMark Diagnostics, Inc. (NASDAQ:GNMK)
In the last trading session, GenMark Diagnostics, Inc. (NASDAQ:GNMK) added its value by -7.02% closing at the price of $4.24. The stock currently has market capitalization of 230.91 Million, with average volume of 482.35 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently GenMark Diagnostics, Inc. (NASDAQ:GNMK) is showing beta of 0.86. This particular value of beta suggests that GenMark Diagnostics, Inc. (NASDAQ:GNMK) has historically moved 86% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for GenMark Diagnostics, Inc. (NASDAQ:GNMK) is at $-1.23.
The stock currently has RSI of 34.71. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor(r) XT-8 system is the second generation in GenMark Dx’s eSensor(r) platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual’s ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual’s increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California.
GenMark Diagnostics, Inc. (NASDAQ:GNMK) topped its 52-week high price of $13.67 on 05/09/17 and 52-Week Low Price of $ 3.63 on 11/06/17. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 7.49% and monthly volatility of 7.00% respectively.